Effect of Enteric-coated mycophenolate sodium on post-transplant infection rate after renal transplantation compared with Mycophenolate mofetil

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-IPR-14005509

Enrollment

Unknown

Registered

2013-11-13

Start date

2009-09-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

End-stage renal disease

Interventions

EC-MPS treatment group:Patients underwent treatment with a standard tripletherapy immunosuppressant protocol consisting of tacrolimus, EC-MPS, and prednisone

MMF treatment group:Patients underwent treatment with a standard tripletherapy immunosuppressant protocol consisting of tacrolimus, MMF, and prednisone

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Patients of either sex, aged 18-65 years, who were recipients of a first living-related donor kidney transplant, and who gave written informed consent, were eligible to participate in the study.

Exclusion criteria

Exclusion criteria: Patients were ineligible to enter the study if they satisfied following criteria: had undergone a previous kidney transplantation; had clinically significant infections requiring continued therapy; positive T-cell crossmatch; ABO incompatibility against donor; panel reactive antibodies (PRAs) more than 20% before transplantation; positive HIV, hepatitis B or C virus infection, thrombocytopenia.

Design outcomes

Primary

Measure	Time frame
The incidence of infection;	—

Secondary

Measure	Time frame
GI AEs;The level of serum creatinine;BPAR;	—

Countries

China

Contacts

Public ContactJun Tian

juntianqlyy@gmail.com+86 0531-82169527

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Mar 5, 2026